VanEck Associates
TGTX icon

VanEck Associates’s TG Therapeutics TGTX Stock Holding History

VanEck Associates’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-17,377
Closed -$628K – 1495
2025
Q3 		$628K Buy
17,377
+10,397
+149% +$342K ﹤0.01% 1156
2025
Q2 		$251K Sell
6,980
-148,165
-96% -$5.52M ﹤0.01% 1233
2025
Q1 		$6.12M Buy
155,145
+14,991
+11% +$504K 0.01% 636
2024
Q4 		$4.22M Buy
+140,154
New +$4.02M 0.01% 749
2021
Q2 		– Sell
-35,483
Closed -$1.71M – 1313
2021
Q1 		$1.71M Buy
+35,483
New +$1.7M ﹤0.01% 642

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

VanEck Associates's TGTX Position: Q4 2025 in Review

VanEck Associates sold out of TG Therapeutics (TGTX) in Q4 2025, closing a stake of 17,377 shares — an estimated $628K sold.

VanEck Associates first reported a position in TGTX in Q1 2021 and held it in 5 quarters. The position peaked at $6.12M in Q1 2025. 352 funds tracked by Wall St. Rank hold TGTX as of Q4 2025.

  • VanEck Associates reported no remaining TG Therapeutics position as of Q4 2025 after selling out during the quarter.
  • VanEck Associates sold 17,377 TG Therapeutics shares in Q4 2025, an estimated $628K.
  • VanEck Associates first reported a position in TG Therapeutics in Q1 2021 and held it in 5 quarters.
  • VanEck Associates's TG Therapeutics position peaked at $6.12M in Q1 2025.
  • 352 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2025.

Based on VanEck Associates's 13F filing for Q4 2025, filed 13 Feb 2026.